4DMedical Ltd (ASX: 4DX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


4DMedical Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $248.53 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 391.39 million
Earnings per share -0.087
Dividend per share N/A
Year To Date Return -12.59%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • 4DMedical Ltd (ASX: 4DX)
    Latest News

    Two smiling work colleagues discuss an investment or business plan at their office.
    Share Gainers

    Why 4DMedical, Orica, PSC Insurance, and REA shares are rising today

    These ASX shares are avoiding the market weakness on Thursday. But why?

    Read more »

    A man sees some good news on his phone and gives a little cheer.
    Share Gainers

    Why 4DMedical, Block, Judo, and Mesoblast shares are pushing higher today

    These ASX shares are avoiding the market weakness. But why?

    Read more »

    A man wearing a white coat and glasses is wide-mouthed in surprise.
    Healthcare Shares

    This ASX healthcare stock is up 12% in 2 days since All Ords inclusion: Should you buy?

    The latest member of the All Ordinaries index is getting some love this week.

    Read more »

    Man drawing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why 4DMedical, A2 Milk, QBE, and Zip shares are charging higher today

    These ASX shares are having a strong start to the week.

    Read more »

    Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
    Small Cap Shares

    2 exciting small-cap ASX shares that could rocket in 2024

    Analysts have put buy ratings on these small caps and see big potential returns.

    Read more »

    A young man wearing a black and white striped t-shirt looks surprised.
    Small Cap Shares

    Broker says these exciting small-cap ASX shares are buys

    These could be top options at the small side of the market.

    Read more »

    Happy diverse colleagues or team of people give high five together to celebrate great teamwork and results.
    Share Gainers

    Why 4DMedical, Iress, Premier Investments, and Tuas shares are pushing higher

    These ASX shares are ending the week on a high.

    Read more »

    A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
    Share Market News

    Guess which ASX healthcare stock is rocketing on an 'unprecedented opportunity' with a global giant

    This healthcare stock is working closely with a giant in its field.

    Read more »

    A man pulls a shocked expression with mouth wide open as he holds up his laptop.
    Small Cap Shares

    Guess why these small cap ASX shares are jumping 10%+ today

    These small caps are making their shareholders smile on Monday.

    Read more »

    a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
    Healthcare Shares

    This ASX medtech stock is roaring 67% higher today on a US approval

    Shareholders of this medtech stock are smiling on Monday.

    Read more »

    a man with a wide, eager smile on his face holds up three fingers.
    Small Cap Shares

    3 exciting small cap ASX shares brokers are tipping as buys

    Brokers are saying good things about these small cap shares in September.

    Read more »

    A young man wearing a black and white striped t-shirt looks surprised.
    Small Cap Shares

    Bell Potter rates these small cap ASX shares as buys

    These could be top options at the small side of the market.

    Read more »

    Frequently Asked Questions

    No, 4DMedical does not pay dividends at this time.

    4DMedical listed on the ASX on 7 August 2020.

    4DX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About 4DMedical Ltd

    4DMedical Ltd (ASX: 4DX) is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.

    The company's non-invasive lung imaging technology emanates from research work undertaken at Monash University. It is the first FDA-cleared respiratory imaging solution that uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data.

    The technology uses existing imaging systems and allows X-ray images to be taken simultaneously from various angles. Using image-processing methods adapted from aerospace engineering, the motion of lung tissue can be measured. This allows ventilation to be calculated at each stage of the breath and at every location within the lung. These measurements are then visualized as a coloured heat map to help medical professionals accurately identify ventilation deficits.

    The 4DMedical technology is patented in key jurisdictions, including the US and Australia. The company is aiming to secure a slice of the global lung imaging market. The US market alone was valued at more than $US30 billion in normal pre-COVID diagnostic conditions.


    4DX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Jun 2024 $0.62 $-0.01 -1.60% 656,714 $0.62 $0.67 $0.62
    14 Jun 2024 $0.63 $-0.01 -1.57% 364,370 $0.65 $0.65 $0.63
    13 Jun 2024 $0.64 $-0.02 -3.08% 722,950 $0.65 $0.65 $0.63
    12 Jun 2024 $0.65 $-0.01 -1.53% 1,557,483 $0.66 $0.66 $0.63
    11 Jun 2024 $0.66 $-0.03 -4.38% 1,453,147 $0.70 $0.72 $0.64
    07 Jun 2024 $0.69 $0.10 16.95% 1,960,306 $0.59 $0.69 $0.59
    06 Jun 2024 $0.59 $0.00 0.00% 282,437 $0.59 $0.60 $0.58
    05 Jun 2024 $0.59 $0.00 0.00% 115,990 $0.59 $0.59 $0.58
    04 Jun 2024 $0.59 $0.02 3.48% 313,811 $0.58 $0.59 $0.57
    03 Jun 2024 $0.58 $-0.02 -3.39% 446,660 $0.60 $0.60 $0.58
    31 May 2024 $0.59 $0.01 1.71% 279,879 $0.59 $0.60 $0.58
    30 May 2024 $0.59 $-0.02 -3.33% 226,437 $0.60 $0.60 $0.58
    29 May 2024 $0.60 $0.00 0.00% 310,077 $0.61 $0.61 $0.59
    28 May 2024 $0.60 $-0.01 -1.64% 41,587 $0.61 $0.62 $0.60
    27 May 2024 $0.61 $0.00 0.00% 189,788 $0.62 $0.62 $0.60
    24 May 2024 $0.61 $0.02 3.36% 155,471 $0.60 $0.62 $0.60
    23 May 2024 $0.60 $0.00 0.00% 167,355 $0.60 $0.60 $0.59
    22 May 2024 $0.60 $0.02 3.45% 209,752 $0.58 $0.60 $0.57
    21 May 2024 $0.58 $-0.02 -3.36% 773,310 $0.60 $0.60 $0.57

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Mar 2024 Geraldine McGinty Exercise 40,000 $29,000
    Exercise of options.
    04 Mar 2024 Lilian (Lil) Bianchi Exercise 40,000 $29,000
    Exercise of options.
    04 Mar 2024 Geraldine McGinty Buy 40,000 $29,000
    Exercise of options.
    04 Mar 2024 Lilian (Lil) Bianchi Buy 40,000 $29,000
    Exercise of options.
    23 Jan 2024 Lilian (Lil) Bianchi Issued 40,000 $31,600
    Director remuneration.
    23 Jan 2024 Geraldine McGinty Issued 40,000 $31,600
    Director remuneration.
    03 Nov 2023 Andreas Fouras Issued 1,306,100 $607,336
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr John Andrew Livingston Executive Director Mar 2018
    Mr John Livingston has lectured in Australia and abroad on the digital radiology environment, as well as business strategies and systems within the commercial sector. John was awarded the AGFA International Award for Development of Digital Imaging Solutions in 2005. John has considerable commercial experience with multiple listed companies.
    Dr Robert Alan Figlin Non-Executive Director Dec 2016
    A nationally recognised leader in genitourinary and thoracic oncology in the United States, Robert's research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership is in developing novel anticancer drugs that avoid the toxicity associated with standard treatments and furthers Cedars Sinai's tradition of compassionate patient care. He is Chair of the Medical Advisory Committee.
    Dr Andreas Fouras Chief Executive OfficerManaging Director Dec 2012
    Dr Andreas Fouras' career in academic research has a foundation gained within studying experimental fluid dynamics. This research into wind tunnel quantification garnered recognition as a young leader in the scientific discipline of fluid dynamics,
    developing a number of new approaches to the imaging of gas and liquid flow. He is a member of the Medical Advisory Committee.
    Ms Lilian (Lil) Bianchi Non-Executive DirectorNon-Executive Chairman Dec 2019
    Ms Lilian Bianchi is an experienced Non-Executive Director and Audit & Risk Chair with a focus on innovative companies operating in highly regulated environments including health, finance, and infrastructure. Her CEO and executive career brought commercial leadership and digital transformation to global listed corporates through to tech startups across US, Australia, India, Singapore, UK, and Europe. She has an international technology research background including programs in health and telecommunications. Her product expertise is in analytics, AI and SaaS where she took to market new products for diverse sectors including FinTech and Transport. Lilian is an independent director and is Chair of the Audit and Risk Committee.
    Mr Julian Bernard Kingsley Sutton Non-Executive Director Sep 2017
    Mr Julian Sutton began his career as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's largest superannuation funds. He later worked for Towers Perrin to Brussels and London as an asset consultant before moving to Credit Suisse Asset Management and then Schroders Investment Management as a portfolio manager in their respective multi-manager teams. After twelve years in London, Julian returned to Australia and formed a sales and marketing business helping best in class international fund management companies establish a presence in the Australian market. Currently, Julian is responsible for the sales and marketing function of Brown Advisory in Australia.
    Dr Geraldine Bernadette McGinty Non-Executive Director Sep 2023
    Dr McGinty became the first woman elected as Chair of the American College of Radiologys (ACR) board of Chancellors. Prior to this, Dr McGinty headed up the ACRs Commission on Economics. Her corporate governance experience includes serving on the Board of NextGen Healthcare (NASDAQ:NXGN), an Atlanta-based provider of software, services and analytical solutions to primary healthcare providers, and as a Non-Executive Director with the Industrial Development Authority (IDA) of the Republic of Ireland, chairing its Audit, Risk and Finance Committee. Dr McGinty is also a member of the Governing Authority of the University of Galway in Ireland. In her various leadership roles. She has also been in identifying and mentoring radiologists who push to address health disparities in research, advocacy efforts, artificial intelligence development, and medical student recruitment. In 2017, Dr McGinty was appointed as founding Academic Director for the Executive MBA and Masters in Healthcare Leadership program delivered jointly by Weill Cornell and the Cornell University SC Johnson School of Business, a role she performed until 2019.
    Ms Naomi Lawrie Company SecretaryGeneral Counsel Apr 2023
    Naomi Lawrie Company SecretaryGeneral Counsel

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Velocimetry Consulting Pty Ltd 64,838,000 18.79%
    BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd 18,106,697 5.25%
    HSBC Custody Nominees (Australia) Limited 7,580,063 2.20%
    Ryder Innovation Fund Lp 6,290,475 1.82%
    National Nominees Limited 3,663,160 1.06%
    J P Morgan Nominees Australia Pty Limited 3,038,117 0.88%
    HSBC Custody Nominees (Australia) Limited – A/C 2 2,884,390 0.84%
    Alex Petrou & Christine Petrou 2,484,471 0.72%
    Mr Damen Diamantopoulos 2,470,000 0.72%
    Netwealth Investments Limited 2,340,650 0.68%
    Citicorp Nominees Pty Limited 2,083,306 0.60%
    Mrs Irene Wai-Ping Lee & Miss Yvonne Lee & Mr Wilson Lee 1,841,379 0.53%
    John Livingston Pty Ltd 1,817,243 0.53%
    Endless Smiles Pty Ltd 1,500,000 0.43%
    BNP Paribas Nominees Pty Ltd 1,480,089 0.43%
    Mr Dev Jayram 1,433,262 0.42%
    Wal Assets Pty Ltd 1,411,487 0.41%
    Chapter 5 Pty Ltd 1,220,697 0.35%
    Jianwen Xiao 1,216,176 0.35%
    AAX Pty Ltd 1,200,000 0.35%